Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Delisting Notification On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain a $1.00 minimum bid price, (the “Bid Price Requirement”) within the 180 day compliance period provided und…

Material Modification to Rights of Security Holders On July 29, 2026, Lexaria Bioscience Corp. (the “Company”) filed a Certificate of Change (the “Certificate”) pursuant to Nevada Revised Statutes (“NRS”) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-15 reverse stock split of the Company’s (a) authorized shares of common stock; and (b) issued and outstanding shares of common stock (the “Reverse Stock Split”). Reason for the Reverse Stock Split The Rever…

Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Bid Price Deficiency Notice On February 4, 2026, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing o…

Entry into a Material Definitive Agreement. On December 14, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share, and (ii) in a…

Unregistered Sale of Equity Securities. The applicable information set forth in

Entry into a Material Definitive Agreement. On September 26, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,666,667 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.50 per share, and (ii) in a…

Unregistered Sale of Equity Securities. The applicable information set forth in

Termination of a Material Definitive Agreement. Effective September 19, 2025, Lexaria Bioscience Corp. (the “Company”) terminated the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (the “Agent”), as originally entered into on August 21, 2024 (the full text having been filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed August 22, 2024) and, as amended by Amendment No. 1 on February 5, 2025 (the full text having been filed as Exhibit 10.1 to…

Entry into a Material Definitive Agreement. On April 24, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with a single institutional investor, pursuant to which the Company agreed to issue and sell to the investor in a registered direct offering (i) 1,925,000 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $1.00 per share, and (ii) pre-fu…

This Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Entry into a Material Definitive Agreement. On February 5, 2025, Lexaria Bioscience Corp. (the “Company”) and JonesTrading Institutional Services LLC (the “Agent”) entered into Amendment No. 1 (the “Amendment”) to the Capital on Demand™ Sales Agreement between the parties originally entered into on August 21, 2024 (the “Original Agreement” and, as amended by the Amendment, the “Sales Agreement”). The Amendment amends the Original Agreement to (i) amend the defined term “Registration Statement…

President and Chief Scientific Officer (CSO) — John Docherty: Mr. Docherty's role was expanded and his compensation terms were updated.

Unregistered Sale of Equity Securities. The applicable information set forth in

Entry into a Material Definitive Agreement. On October 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor (i) in a registered direct offering, 1,633,987 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $3.06 per share, and (ii) in…

Chief Financial Officer — Michael Shankman: Michael Shankman was appointed as the new Chief Financial Officer, replacing Nelson Cabatuan who resigned.

CEO — Christopher Bunka: Christopher Bunka resigned as CEO and received a severance package.

Entry into a Material Definitive Agreement. On August 21, 2024, Lexaria Bioscience Corp. (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time, up to $20,000,000 in aggregate principal amount of shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, through or to the Agent, as the Company’s sales agent or…

Chief Financial Officer — Mr. Nelson Cabatuan: Mr. Cabatuan resigned from his position as CFO to focus on other roles.

Unregistered Sale of Equity Securities. The information in

above was offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the shares of common stock issuable upon the exercise thereof, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. The securities were offered only to accredited invest…

Chief Financial Officer — Nelson Cabatuan: Nelson Cabatuan was appointed as the new Chief Financial Officer of Lexaria Bioscience Corp.

Unregistered Sale of Equity Securities. The applicable information set forth in

Entry into a Material Definitive Agreement. On February 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors (i) in a registered direct offering, 1,444,741 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $2.31 per share, and pre-funded warra…